Browse News
Filter News
Found 69 articles
-
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
11/14/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter operating and financial results.
-
Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
11/1/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR) today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference, taking place in New York, NY from November 6 - 7, 2023.
-
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
10/3/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company’s Board of Directors, effective today.
-
Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference
8/31/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a panel discussion and 1x1 investor meetings at the Citi 18th Annual BioPharma Conference, taking place in Boston, MA from September 5 - 7, 2023.
-
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
8/10/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter operating and financial results.
-
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601’s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial
7/25/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601 in patients with Friedreich's ataxia (FA) to proceed to a 50 mg cohort in which participants will be dosed daily for the first 14 days, and then every other day until day 28.
-
Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer
7/17/2023
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced the appointment of Russell “Rusty” Clayton, DO, as Chief Medical Officer.
-
Larimar Therapeutics Set to Join Russell 3000® Index
6/21/2023
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023, according to a preliminary list of additions posted May 19, 2023.
-
Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results
5/15/2023
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced preliminary top-line data from the 25 mg cohort of its Phase 2, four-week, placebo-controlled, dose exploration trial of CTI-1601 in participants with Friedreich’s ataxia.
-
Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days
3/28/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim Genomic Medicines and Rare Disease Days, which are taking place from April 3 – 4, 2023.
-
Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results
3/14/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2022 operating and financial results.
-
The FDA greenlit Reata Pharmaceuticals' omaveloxolone (Skyclarys) as the first and only treatment for Friedreich’s ataxia, a rare, life-limiting neuromuscular disorder.
-
There are currently no disease-modifying treatments for Friedreich’s ataxia. That could change when the FDA makes a decision about Reata Pharmaceuticals’ omaveloxolone on Feb. 28.
-
Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer
2/7/2023
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Gopi Shankar, PhD, MBA, FAAPS, to the newly created position of Chief Development Officer (CDO).
-
BioSpace spoke with four veterans in the field about the less obvious reasons why companies with good science may still fail.
-
Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
11/21/2022
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will present and participate in 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference, which is taking place in New York, NY from November 29 – December 1, 2022.
-
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
11/10/2022
Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its third quarter 2022 operating and financial results.
-
Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
11/7/2022
Larimar Therapeutics, Inc. announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022.
-
Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
10/20/2022
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the issuance of U.S. Patent No. 11,459,363.
-
Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
10/19/2022
Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in three presentations at the upcoming International Congress for Ataxia Research.